An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer over the last decade. These inhibitors are currently established as first- and second-line systemic trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanciu, Ioana-Miruna, Parosanu, Andreea Ioana, Nitipir, Cornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526227/
https://www.ncbi.nlm.nih.gov/pubmed/37759823
http://dx.doi.org/10.3390/biom13091422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526227/
https://www.ncbi.nlm.nih.gov/pubmed/37759823
http://dx.doi.org/10.3390/biom13091422

Ejemplares similares